BR112012026641A2 - compostos antivirais - Google Patents

compostos antivirais

Info

Publication number
BR112012026641A2
BR112012026641A2 BR112012026641A BR112012026641A BR112012026641A2 BR 112012026641 A2 BR112012026641 A2 BR 112012026641A2 BR 112012026641 A BR112012026641 A BR 112012026641A BR 112012026641 A BR112012026641 A BR 112012026641A BR 112012026641 A2 BR112012026641 A2 BR 112012026641A2
Authority
BR
Brazil
Prior art keywords
compounds
antiviral compounds
rig
pathway
viral infection
Prior art date
Application number
BR112012026641A
Other languages
English (en)
Inventor
Kristin Bedard
Shawn P Iadonato
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of BR112012026641A2 publication Critical patent/BR112012026641A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Abstract

compostos antivirais. aqui são revelados compostos e composições relacionadas para o tratamento de infecção viral, incluindo infecção de rna vira, e compostos que podem modular a via de rig-i em células de vertebrados, incluindo os compostos que podem ativar a via rig-i.
BR112012026641A 2010-04-23 2011-04-20 compostos antivirais BR112012026641A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32756610P 2010-04-23 2010-04-23
PCT/US2011/033326 WO2011133722A2 (en) 2010-04-23 2011-04-20 Anti-viral compounds

Publications (1)

Publication Number Publication Date
BR112012026641A2 true BR112012026641A2 (pt) 2016-07-12

Family

ID=44834797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026641A BR112012026641A2 (pt) 2010-04-23 2011-04-20 compostos antivirais

Country Status (12)

Country Link
US (1) US8927561B2 (pt)
EP (1) EP2560656A4 (pt)
JP (1) JP2013525366A (pt)
KR (1) KR20130069640A (pt)
CN (1) CN102939088A (pt)
AU (1) AU2011242683A1 (pt)
BR (1) BR112012026641A2 (pt)
CA (1) CA2812043A1 (pt)
IL (1) IL222634A0 (pt)
MX (1) MX2012012353A (pt)
TW (1) TW201202244A (pt)
WO (1) WO2011133722A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101965336B (zh) 2008-01-04 2015-06-17 英特利凯恩有限责任公司 某些化学实体、组合物和方法
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
US20140227321A1 (en) * 2011-09-30 2014-08-14 Kineta, Inc. Anti-viral compounds
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Conversion of tricyclic compounds as FGFR inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
PL3421462T3 (pl) 2013-06-27 2023-09-11 Pfizer Inc. Związki heteroaromatyczne i ich zastosowanie jako ligandów dopaminy d1
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
JP6502939B2 (ja) 2013-11-22 2019-04-17 シーエル バイオサイエンシズ リミティド ライアビリティ カンパニー 骨粗鬆症の処置及び予防のためのガストリン拮抗薬
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
CN103695543B (zh) * 2013-12-16 2016-04-06 中国人民解放军第二军医大学 模式识别受体rig-i在制备肿瘤诊断或预后评估试剂盒中的应用
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
JP6978424B2 (ja) 2016-04-15 2021-12-08 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
IL263824B2 (en) 2016-06-20 2023-10-01 Incyte Corp Crystals in solid form in the presence of an inhibitor
JP7054681B2 (ja) 2016-06-24 2022-04-14 インフィニティー ファーマシューティカルズ， インコーポレイテッド 組合せ療法
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000065885A (ko) 1999-04-10 2000-11-15 최승주 항바이러스성 피리미딘다이온 유도체 및 그 제조방법
US7947691B2 (en) * 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
JP5390407B2 (ja) * 2007-03-06 2014-01-15 ノバルティス アーゲー 炎症またはアレルギー症状の処置に適する二環式有機化合物
WO2008109177A2 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8518960B2 (en) * 2007-05-23 2013-08-27 Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法

Also Published As

Publication number Publication date
WO2011133722A3 (en) 2012-04-05
WO2011133722A2 (en) 2011-10-27
KR20130069640A (ko) 2013-06-26
IL222634A0 (en) 2012-12-31
EP2560656A2 (en) 2013-02-27
EP2560656A4 (en) 2013-11-27
JP2013525366A (ja) 2013-06-20
AU2011242683A1 (en) 2012-12-13
US20130045229A1 (en) 2013-02-21
TW201202244A (en) 2012-01-16
US8927561B2 (en) 2015-01-06
CA2812043A1 (en) 2011-10-27
MX2012012353A (es) 2013-02-07
CN102939088A (zh) 2013-02-20

Similar Documents

Publication Publication Date Title
BR112012026641A2 (pt) compostos antivirais
BR112012026644A2 (pt) compostos antivirais
MX2014003889A (es) Compuestos antivirales.
WO2011133729A3 (en) Anti-viral compounds
SV2017005561A (es) Metodos para tratar infecciones por el virus filoviridae
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR112013019643A2 (pt) inibidores de alk, uso e composição farmacêutica compreendendo os mesmos
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
CO7160104A2 (es) Inhibidores de virus de hepatitis c
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
WO2011133727A3 (en) Anti-viral compounds
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
UY33735A (es) Compuestos antivirales
CR11519A (es) Vectores de virus oncoliticos de viruela
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BR112012021406A8 (pt) Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
MX351818B (es) Compuestos antivirales.
BR112015011224A2 (pt) misturas de reação de pcr e métodos de usar as mesmas
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
EA201201177A1 (ru) Димерные ингибиторы iap

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]